Study S001880

Evaluating the Effects of GLP-1 Analogue, Oral Semaglutide, in Patients With Alzheimer's Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07200622
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 60
Start: 2025-09-25
Primary completion: 2027-12-31
Lead sponsor: Imperial College London
Conditions: Alzheimer Disease
Interventions: DRUG:Semaglutide (Rybelsus®); DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

To evaluate the safety and tolerability of oral semaglutide in an AD population. [Adverse events monitoring: Baseline; Weeks 4, 8, 26, 39, 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.